Accession Number:

ADA148919

Title:

Army Drug Development Program. Phase 1. Clinical Testing

Descriptive Note:

Annual rept. Feb 1980-Jan 1981

Corporate Author:

BIO-MED INC COLLEGE PARK MD

Personal Author(s):

Report Date:

1981-02-01

Pagination or Media Count:

213.0

Abstract:

Studies of WR 180,409 H3PO4, a Pyridinemethanol with all subjects developed mild gastrointestinal symptoms after receiving 750 mg of the drug orally. WR 171,669, a phenanthrene methanol with demonstrated activity against chloroquine resistant P. Falciparum malaria, was studied in a single dose, double-blind, rising dose schedule in 28 subjects. In a study of the pharmacokinetics of WR 229, 870 Sodium Stibogluconate Injection, BP a single intravenous dose of 600 mg of Pentostam was given to eight subjects. No acute intolerance developed. In previous studies of WR 194,965 H3PO4 an antimalarial of the Mannich base class, the top tolerated single dose in man was found to be less than the dose that cured 100 of Aotus monkeys infected with falciparum malaria.

Subject Categories:

  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE